Skip to main content

Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study)

Background

A strong inverse relationship between the plasma concentration of HDL-C and the incidence of coronary heart disease is widely accepted. Few interventions have succeeded to increase plasma HDL levels in HIV-infected pts. NVP has a favorable lipid profile, and clinical trials have suggested that it could have a differential effect on plasma HDL-C levels.

Methods

Prospective, single arm, multicenter study. We included patients on stable antiretroviral therapy with HIV RNA ≤50 copies/mL for at least one year that were switched to a NVP-containing regimen. Patients receiving lipid lowering therapy were excluded. HDL-cholesterol and other lipid parameters at baseline and after 24 weeks of treatment with NVP are compared.

Results

Among 130 pts included in the study, 119 (91%) could be evaluated. BL characteristics: median age 44, female 24%, current smokers 53%. Previous AIDS 29%, CD4 count 502/mm3. Time on ARV therapy 42 months. Previous therapy: efavirenz 38%, 3 NRTI 12%, PI 50%. Accompanying nucleosides were tenofovir/emtricitabine in 69%, and abacavir/lamivudine in 31%.

Table 1 shows the 24-week results of lipid profile.

Table 1

At 24 week, the proportion of patients with HDL-C>40 mg/dl were 69.7% (95%CI 60.7-77.8), compared to 52.1% (95%CI 42.8-61.3) before taking NVP (p<0.01). The Framingham risk score decreased from 7.6 to 6.6 (p<0.05) after switching to NVP.

Conclusions

Switching to NVP-containing regimens in patients on stable therapy is associated with a significant increase in HDL-C and decrease in TC/HDL-c, with an overall improvement in the Framingham score.

Author information

Authors and Affiliations

Authors

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Rodriguez, J., Delgado, M., Viciana, P. et al. Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study). JIAS 13, P79 (2010). https://doi.org/10.1186/1758-2652-13-S4-P79

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1758-2652-13-S4-P79

Keywords

  • Efavirenz
  • Nevirapine
  • Lipid Lowering Therapy
  • Framingham Risk Score
  • Strong Inverse Relationship